Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.76 |
| ▸ | CA9 | Q16790 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 2/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.74 |
| ▸ | NPC1 | O15118 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | ACR | P10323 | 2/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.61 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.61 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.61 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152359 | 0.86 | ALPL (1.00) | ALPLCA9MAPTALDH1A1LMNA | |
| SCHEMBL1414008 | 0.85 | MAPT (1.00) | ALPLCA9MAPTALDH1A1LMNA | |
| SCHEMBL11982068 | 0.84 | MAPT (0.76) | ALPLCA9MAPTALDH1A1LMNA | |
| SCHEMBL29444415 | 0.83 | ALPL (0.73) | ALPLCA9MAPTALDH1A1LMNA | |
| SCHEMBL27028221 | 0.81 | SCN9A (0.60) | ALPLCA9MAPTALDH1A1LMNA | |
| SCHEMBL2888912 | 0.80 | MAPT (1.00) | ALPLCA9MAPTALDH1A1LMNA | |
| SCHEMBL4638840 | 0.80 | ALPL (0.73) | ALPLACRHDAC3HDAC4HDAC1 | |
| SCHEMBL2846632 | 0.80 | ALPL (0.73) | ALPLMAPTALDH1A1ACRHPGD | |
| SCHEMBL18726258 | 0.80 | ACR (0.57) | ALPLCA9MAPTALDH1A1LMNA | |
| SCHEMBL2789578 | 0.79 | TP53 (0.74) | ALPLMAPTALDH1A1L3MBTL1ACR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057646-B | Pyrazole derivative and application thereof in preparation of antitumor drugs | 常州大学 | 2023-05-02 | — | — | CN | disclosed |
| CN-114057646-A | Pyrazole derivative and application thereof in preparation of antitumor drugs | 常州大学 | 2022-02-18 | — | — | CN | disclosed |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010009290-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| EP-2118067-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | Siena Biotech S.p.A. (IT) | 2009-11-18 | — | — | EP | disclosed |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-10-22 | — | — | US | disclosed |
| WO-2009091832-A1 | SYNTHESIS OF PYRAZOLES | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091831-A1 | COMPOUND FORMS AND USES THEREOF | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091813-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | WYETH (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090181953-A1 | COMPOUND FORMS AND USES THEREOF | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-20090181952-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| WO-2008087529-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH S.P.A. (IT) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181953-A1 | COMPOUND FORMS AND USES THEREOF | REN, PKD1, RCC1 | ALPL 2169/4885CA9 27/4885MAPT 1131/4885 |
| US-20100029606-A1 | MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF | CHRNA7, CHRNA2, CHRNA6 | ALPL 3280/4885CA9 4020/4885MAPT 933/4885 |
| US-20100130474-A1 | ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS | CHRNA7, CHRNA6, CHRNA2 | ALPL 4210/4885CA9 3775/4885MAPT 501/4885 |
| US-20090181952-A1 | COMPOUNDS USEFUL AS ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA2, CHRNA6 | ALPL 3768/4885CA9 4025/4885MAPT 505/4885 |
| US-20090264648-A1 | SYNTHESIS OF PYRAZOLES | CHRNA7, CHRNA5, CHRNA3 | ALPL 3888/4885CA9 4357/4885MAPT 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.